Prometheus to Sell Rosetta Genomics' Tests; Takes Equity Stake | GenomeWeb

NEW YORK (GenomeWeb News) – Prometheus Laboratories has licensed US rights to Rosetta Genomics' recently introduced microRNA-based tests and has taken an equity stake in the molecular diagnostics firm.

San Diego-based Prometheus has gained the right to sell the miRview mets, miRview squamous, and miRview meso, which Rosetta launched in late 2008. It will provide Rosetta with payments, either in the form of milestones or R&D funding, and royalties based on net sales in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.